Clinical trials: Mosquito-Borne Diseases
Malaria
Study of Factors Involved in Resistance to Severe Malaria
This study will examine whether resistance to severe malaria is associated with weakening of a specific immune response (TLR-mediated pro-inflammatory cytokine response).
- Trial name
- NCT00368810
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Virus Infection
Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update
The primary objective of the study is to evaluate the effectiveness of additional risk minimization measures material by assessing the knowledge and understanding of healthcare professionals regarding the key safety messages…
- Trial name
- DNG00042 (NCT04170140)
- Testing
- No intervention
- Where
- France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Blood Donors, Dengue
Dengue Seroprevalence Study in Blood Donors in the French West Indies
Dengue is an infectious disease most prevalent in the world. This disease is endemic in the Caribbean, with an increase in seasonal rains.
- Trial name
- DengSeroprevAn (NCT01104740)
- Testing
- Biological sample collection
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 817 people, healthy volunteers welcome
- Sponsor
- Etablissement Français du Sang, Martinique
Malaria
Pharmacokinetic Study of Multi-dose Chloroquine
Chloroquine (CQ) remains an alternative cheap, safe and widely available drug. Our previous research has shown that double (50 mg/kg) standard dose CQ given in split doses had a 95% efficacy and was well tolerated and safe.
- Trial name
- NCT01814423
- Testing
- Chloroquine-base 50 mg, Chloroquine-base 70 mg
- Where
- Guinea-Bissau
- Volunteers
- 30 people
- Sponsor
- Bandim Health Project
Plasmodium Vivax Malaria Without Complication
Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia
Both artemether-lumefantrine and chloroquine are currently used and recommended by Malaysian Ministry of Health as blood stage treatments for non-severe P. vivax and P. knowlesi malaria.
- Trial name
- PRIMAL (NCT02348788)
- Testing
- Artemether-lumefantrine + Primaquine, Chloroquine + Primaquine
- Where
- 3 sites in Malaysia
- Volunteers
- 98 people
- Sponsor
- Menzies School of Health Research
Dengue
Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).
Dengue is one of the most epidemiologically and clinically relevant arboviral diseases, affecting half of the global population.
- Trial name
- RIMVADE (NCT07158190)
- Testing
- Vaccine
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Malaria
Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers
This is a first-in-human study of MMV390048. The study will evaluate the safety, tolerability and pharmacokinetic properties of escalating single and multiple doses of MMV390048 when administered to healthy male volunteers and…
- Trial name
- NCT02230579
- Testing
- MMV390048 5mg, MMV390048 20mg, MMV390048 40mg
- Where
- South Africa
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Parasitic Diseases, Bacterial Diseases
Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination
The purpose of this study is to determine whether the triple co administration of albendazole, ivermectin and azithromycine is as safe as the current treatment scheme that consists to treat with albendazole plus ivermectin…
- Trial name
- AZIVAL (NCT01586169)
- Testing
- triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
- Where
- Mali
- Volunteers
- 3,000 people
- Sponsor
- Centre d'Appui à la lutte contre la Maladie
Tuberculosis, Diphtheria
Evaluation of an Infant Immunization Encouragement Program in Nigeria
Previous studies have shown that a small incentive can have a large impact on health behaviors like vaccinating children. New Incentives, an international non-governmental organization (NGO), aims to boost demand for immunization…
- Conditions
- Tuberculosis, Diphtheria, Tetanus, Pertussis
- Trial name
- NCT03870061
- Testing
- All Babies Are Equal Initiative (conditional cash transfer program)
- Where
- 3 sites in Nigeria
- Volunteers
- 5,187 people, healthy volunteers welcome
- Sponsor
- GiveWell
Malaria
Evaluation of IR3535 as a Spatial Repellent for Malaria Control.
Mozambique contributes with 5% of global malaria cases, and despite control efforts the Sofala province continues to experience a high burden of malaria.
- Trial name
- REPELMALARIA (NCT04419766)
- Testing
- IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester) house spraying
- Where
- Mozambique
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Universidade Nova de Lisboa
Malaria,Falciparum
First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367
This three-part, first-in-human, healthy volunteer study aims to assess the safety and tolerability of the test medicine as well as how it is taken up by the body when given as single and multiple doses.
- Trial name
- NCT05507970
- Testing
- MMV367, MMV367 (Fed 440mg), MMV367 (Fasted 440mg)
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Japanese Encephalitis, Measles
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
This is a phase IV, randomized, controlled, open-label study proceed in healthy children aged 8 months in China. The primary objective is to demonstrate the immunogenicity of simultaneous administration of JEV-I and MMR is not…
- Conditions
- Japanese Encephalitis, Measles, Mumps, Rubella
- Trial name
- NCT06331702
- Testing
- Vero cell-drived inactive Japanese encephalitis vaccine, Measles-Mumps-Rubella Vaccine
- Where
- China
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Tropical Disease
A Pilot Study Examining for the Presence of Fecal Coliforms and Tropical Diseases in Peru
Tropical diseases are continuously on the rise throughout the world as they are spreading and manifesting in various locations globally.
- Trial name
- NCT03078894
- Testing
- Zika, Chikagunya, Dengue
- Where
- 4 sites in Peru
- Volunteers
- 100 people
- Sponsor
- BioRed LLC
Malaria
Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali
Background: Malaria is still a health problem in Sub-Saharan Africa. Death rates are stable and have even increased in some areas. There are malaria vaccines.
- Trial name
- NCT02627456
- Testing
- PfSPZ Vaccine, PfSPZ Challenge Material, PBS and HSA Diluent
- Where
- Mali
- Volunteers
- 409 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
This first-in-human clinical trial, was a dose escalation multi-center trial designed to assess the safety, tolerability, and immunogenicity of the vaccine component, BNT165b1, a ribonucleic acid (RNA)-lipid nanoparticle (LNP)…
- Trial name
- NCT05581641
- Testing
- BNT165b1
- Where
- 5 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Travel-Related Illness, Malaria
Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
The investigators hypothesize that sex, age, area of exposure and purpose of travel are associated with different travel-related infections. The investigators also hypothesize that certain infections will have long-term sequelae.
- Conditions
- Travel-Related Illness, Malaria, Dengue, Chikungunya
- Trial name
- ITIT (NCT04672577)
- Testing
- Observational study
- Where
- Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Patricia Schlagenhauf
Malaria, Malaria,Falciparum
A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines
Malaria is a major public health problem. There were around 240 million cases of malaria and 627,000 deaths worldwide in 2020. There is a great need for a safe, effective malaria vaccine and the team at University of Oxford is…
- Conditions
- Malaria, Malaria,Falciparum, Parasitic Disease, Vector Borne Diseases
- Trial name
- NCT05978037
- Testing
- RH5.1 and/or RH5.2-VLP with Matrix-M
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine
This study will be the fourth time that the candidate malaria vaccine Merozoite Surface Protein - long synthetic chain, will be tested in malaria endemic populations.in the past,once tested in adults and twice in children proved…
- Trial name
- NCT00652275
- Testing
- MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP, Verorab vaccine
- Where
- Mali
- Volunteers
- 378 people, healthy volunteers welcome
- Sponsor
- African Malaria Network Trust
Malaria, Malaria Prophylaxis
Boosting the Impact of SMC Through Simultaneous Screening and Treatment of Roommates
Malaria represents a major public health concern in sub-Sahara Africa. Seasonal malaria chemoprevention (SMC) is one of the largest preventive measures.
- Conditions
- Malaria, Malaria Prophylaxis, Mass Testing and Treatment
- Trial name
- SMC-RST (NCT04816461)
- Testing
- Amodiaquine Sulfadoxine-Pyrimethamin administration, Dihydroartemisinin-Piperaquine, Standard HRP2-RDT
- Where
- Burkina Faso
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche en Sciences de la Sante, Burkina Faso
Malaria, Falciparum
Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults
The primary objective is to evaluate the safety of 3 doses given at D0, W4, and W26 of 50 µg dosage of AMA1-DiCo adjuvanted either with GLA-SE or Alhydrogel® in healthy European adults not previously exposed to the parasite…
- Trial name
- AMA1-DiCo (NCT02014727)
- Testing
- Group A1 : 50µg AMA1-DiCo + Alhydrogel, Group A2 : 50 µg AMA1-DiCo+ GLA-SE
- Where
- 2 sites in Burkina Faso, France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.